Production (Stage)
Edgewise Therapeutics, Inc.
EWTX
$15.29
-$0.13-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.86% | -16.21% | -8.36% | -10.42% | 5.37% |
| Total Depreciation and Amortization | -11.92% | 4.49% | 12.73% | 1.71% | -1.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.97% | 41.07% | 117.83% | -2.91% | -42.27% |
| Change in Net Operating Assets | -168.55% | 176.20% | -21.30% | 237.69% | -1,053.73% |
| Cash from Operations | -40.47% | 1.52% | -4.89% | 8.74% | -6.59% |
| Capital Expenditure | 83.94% | 47.31% | -135.29% | 25.59% | -84.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 107.31% | -18.11% | -31.14% | 114.03% | -1,087.37% |
| Cash from Investing | 109.82% | -17.51% | -32.13% | 113.93% | -1,094.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -21.90% | -18.38% | 77.35% | -99.17% | 355.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -345.83% | -- | -- |
| Cash from Financing | -23.21% | -13.14% | 70.75% | -99.19% | 354.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 362.90% | -337.70% | -90.01% | 123.68% | -205.07% |